JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

474.51 2.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

470.92

Максимум

478.69

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
Марж на печалбата	-39.75
Служители	528
EBITDA	-68M -106M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+47.73% upside

Дивиденти
By Dow Jones
Следващи печалби	19.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.9B 11B
Предишно отваряне	471.53
Предишно затваряне	474.51

Настроения в новините

By Acuity

11%

89%

5 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.02.2026 г., 02:46 ч. UTC

Придобивния, сливания и поглъщания

Big Money, High Anxiety -- Barrons.com

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6.02.2026 г., 20:27 ч. UTC

Печалби

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6.02.2026 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6.02.2026 г., 19:48 ч. UTC

Печалби

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6.02.2026 г., 19:17 ч. UTC

Пазарно говорене

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6.02.2026 г., 18:50 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 18:47 ч. UTC

Пазарно говорене

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6.02.2026 г., 18:34 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6.02.2026 г., 17:58 ч. UTC

Печалби

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

47.73% нагоре

12-месечна прогноза

Среден 705.56 USD 47.73%

Висок 964 USD

Нисък 570 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

5 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.